Oruka Therapeutics (ORKA) Change in Accured Expenses (2010 - 2026)

Oruka Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 156.28% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at $3.6 million (down 32.83% YoY), while the FY2025 annual figure was $7.2 million, up 120.08% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.3 million, down from $2.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.8 million in Q3 2025, with the low at -$2.1 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is $51000.0 (2022), against an average of $457235.3.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses slumped 1388.89% in 2023, then soared 1142.22% in 2024.
• Oruka Therapeutics' Change in Accured Expenses stood at -$342000.0 in 2022, then decreased by 24.85% to -$427000.0 in 2023, then surged by 484.54% to $1.6 million in 2024, then jumped by 34.41% to $2.2 million in 2025, then slumped by 159.08% to -$1.3 million in 2026.
• Business Quant data shows ORKA's Change in Accured Expenses at -$1.3 million in Q1 2026, $2.2 million in Q4 2025, and $4.8 million in Q3 2025.